TY - JOUR
T1 - Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
AU - and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas
AU - Imai, Reiko
AU - Kamada, Tadashi
AU - Araki, Nobuhito
AU - Abe, Satoshi
AU - Iwamoto, Yukihide
AU - Ozaki, Toshifumi
AU - Chuman, Hirokazu
AU - Hiraga, Hiroaki
AU - Hiruma, Toru
AU - Kameda, Noriaki
AU - Kanehira, Chihiro
AU - Kaya, Mitsunori
AU - Machinami, Rikuo
AU - Matsumine, Akihiko
AU - Matsumoto, Seiichi
AU - Morioka, Hideo
AU - Nishida, Yoshihiro
AU - Takahashi, Kazuhisa
AU - Tsuneyoshi, Masazumi
AU - Yamaguchi, Takehiko
AU - Yonemoto, Tsukasa
N1 - Publisher Copyright:
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2018/9
Y1 - 2018/9
N2 - Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.
AB - Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.
KW - carbon ion radiotherapy
KW - charged particle therapy
KW - radiotherapy
KW - soft tissue sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85050369837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050369837&partnerID=8YFLogxK
U2 - 10.1002/cam4.1679
DO - 10.1002/cam4.1679
M3 - Article
C2 - 30030906
AN - SCOPUS:85050369837
VL - 7
SP - 4308
EP - 4314
JO - Cancer Medicine
JF - Cancer Medicine
SN - 2045-7634
IS - 9
ER -
